Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model

R. Lawson, P. Čechová, E. Zarrouk, J. Javellaud, V. Bazgier, M. Otyepka, P. Trouillas, N. Picard, P. Marquet, F. Saint-Marcoux, S. El Balkhi

. 2023 ; 180 (7) : 829-842. [pub] 20220122

Language English Country England, Great Britain

Document type Journal Article

E-resources Online Full text

NLK Free Medical Journals from 1968 to 1 year ago
Europe PubMed Central from 1968 to 1 year ago
Medline Complete (EBSCOhost) from 2002-01-01 to 1 year ago
Wiley Free Content from 1997 to 1 year ago

BACKGROUND AND PURPOSE: Opioids and benzodiazepines are frequently combined in medical as well as in non-medical contexts. At high doses, such combinations often result in serious health complications attributed to pharmacodynamics interactions. Here, we investigate the contribution of the metabolic interactions between oxycodone, diazepam and diclazepam (a designer benzodiazepine) in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. EXPERIMENTAL APPROACH: A preparation of pooled human liver microsomes was used to study oxycodone metabolism in the presence or absence of diazepam or diclazepam. In mice, diazepam or diclazepam was concomitantly administered with oxycodone to mimic acute intoxication. Diclazepam was introduced on Day 10 in mice continuously infused with oxycodone for 15 days to mimic chronic intoxication. In silico modelling was used to study the molecular interactions of the three drugs with CYP3A4 and 2D6. KEY RESULTS: In mice, in acute conditions, both diazepam and diclazepam inhibited the metabolism of oxycodone. In chronic conditions and at pharmacologically equivalent doses, diclazepam drastically enhanced the production of oxymorphone. In silico, the affinity of benzodiazepines was higher than oxycodone for CYP3A4, inhibiting oxycodone metabolism through CYP3A4. Oxycodone metabolism is likely to be diverted towards CYP2D6. CONCLUSION AND IMPLICATIONS: Acute doses of diazepam or diclazepam result in the accumulation of oxycodone, whereas chronic administration induces the accumulation of oxymorphone, the toxic metabolite. This suggests that overdoses of opioids in the presence of benzodiazepines are partly due to metabolic interactions, which in turn explain the patterns of toxicity dependent on usage. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003732
003      
CZ-PrNML
005      
20230425140837.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bph.15765 $2 doi
035    __
$a (PubMed)34855983
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lawson, Roland $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $1 https://orcid.org/0000000206848809
245    10
$a Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model / $c R. Lawson, P. Čechová, E. Zarrouk, J. Javellaud, V. Bazgier, M. Otyepka, P. Trouillas, N. Picard, P. Marquet, F. Saint-Marcoux, S. El Balkhi
520    9_
$a BACKGROUND AND PURPOSE: Opioids and benzodiazepines are frequently combined in medical as well as in non-medical contexts. At high doses, such combinations often result in serious health complications attributed to pharmacodynamics interactions. Here, we investigate the contribution of the metabolic interactions between oxycodone, diazepam and diclazepam (a designer benzodiazepine) in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. EXPERIMENTAL APPROACH: A preparation of pooled human liver microsomes was used to study oxycodone metabolism in the presence or absence of diazepam or diclazepam. In mice, diazepam or diclazepam was concomitantly administered with oxycodone to mimic acute intoxication. Diclazepam was introduced on Day 10 in mice continuously infused with oxycodone for 15 days to mimic chronic intoxication. In silico modelling was used to study the molecular interactions of the three drugs with CYP3A4 and 2D6. KEY RESULTS: In mice, in acute conditions, both diazepam and diclazepam inhibited the metabolism of oxycodone. In chronic conditions and at pharmacologically equivalent doses, diclazepam drastically enhanced the production of oxymorphone. In silico, the affinity of benzodiazepines was higher than oxycodone for CYP3A4, inhibiting oxycodone metabolism through CYP3A4. Oxycodone metabolism is likely to be diverted towards CYP2D6. CONCLUSION AND IMPLICATIONS: Acute doses of diazepam or diclazepam result in the accumulation of oxycodone, whereas chronic administration induces the accumulation of oxymorphone, the toxic metabolite. This suggests that overdoses of opioids in the presence of benzodiazepines are partly due to metabolic interactions, which in turn explain the patterns of toxicity dependent on usage. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    12
$a oxykodon $7 D010098
650    _2
$a oxymorfon $7 D010111
650    _2
$a cytochrom P-450 CYP3A $7 D051544
650    _2
$a benzodiazepiny $x toxicita $7 D001569
650    _2
$a diazepam $x farmakologie $7 D003975
650    _2
$a opioidní analgetika $x toxicita $7 D000701
650    _2
$a modely u zvířat $7 D023421
650    12
$a předávkování léky $7 D062787
655    _2
$a časopisecké články $7 D016428
700    1_
$a Čechová, Petra $u Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czechia $1 https://orcid.org/0000000250696398
700    1_
$a Zarrouk, Eliès $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France
700    1_
$a Javellaud, James $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France
700    1_
$a Bazgier, Václav $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, Olomouc, Czechia
700    1_
$a Otyepka, Michal $u Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czechia
700    1_
$a Trouillas, Patrick $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czechia
700    1_
$a Picard, Nicolas $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France
700    1_
$a Marquet, Pierre $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France
700    1_
$a Saint-Marcoux, Franck $u University of Limoges, IPPRITT, Limoges, France $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France
700    1_
$a El Balkhi, Souleiman $u INSERM, IPPRITT, U1248, Limoges, France $u Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France $1 https://orcid.org/0000000297435603
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 180, č. 7 (2023), s. 829-842
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34855983 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140833 $b ABA008
999    __
$a ok $b bmc $g 1924420 $s 1189941
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 180 $c 7 $d 829-842 $e 20220122 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...